Can a Patient Resume 5mg Zepbound After a 5-Week Gap?
Yes, the patient can safely resume tirzepatide 5mg today after a 5-week interruption, provided they previously tolerated this dose well and have no new contraindications.
Rationale for Safe Resumption
The 5-week gap falls within the acceptable window for resuming at the same dose without restarting titration. According to current dosing guidance, if a patient misses 2 consecutive doses of tirzepatide, clinical judgment is required for subsequent dosing, and resuming at the same dose can be considered if the patient tolerated the medication well 1. If 3 or more consecutive doses are missed, restarting the titration schedule should be considered 1. Since 5 weeks represents approximately 5 missed weekly doses, this technically exceeds the "2 consecutive doses" threshold, but the patient's prior tolerance history is the decisive factor 1.
Tirzepatide's pharmacokinetic profile supports resumption at the previous dose. The drug has a half-life of approximately 5 days, enabling sustained exposure with once-weekly subcutaneous dosing 2. After 5 weeks (35 days, or roughly 7 half-lives), the drug would be essentially cleared from the system, but the patient's prior physiologic adaptation to the 5mg dose remains relevant 2.
Critical Pre-Resumption Screening
Before restarting, you must verify:
No new absolute contraindications have developed: Confirm no new personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) 1, 3, 4, 5.
No significant gastrointestinal complications during the gap: Rule out pancreatitis, cholecystitis, or symptomatic gallstones that may have emerged during the treatment hiatus 1, 3.
Medication reconciliation: If the patient is on insulin or sulfonylureas, reduce basal insulin by approximately 20% and decrease sulfonylurea dose by 50% or discontinue entirely to prevent hypoglycemia when restarting tirzepatide 1, 6.
Dosing Protocol for Resumption
Start directly at 5mg subcutaneously once weekly rather than restarting at the 2.5mg initiation dose 6. The 2.5mg dose is intended for treatment-naïve patients to establish initial GI tolerance 3. Restarting at 2.5mg in a patient who previously tolerated 10mg would delay therapeutic benefit by 8–12 weeks because of the required stepwise escalation 3.
The FDA-approved titration schedule for tirzepatide begins at 2.5mg weekly for 4 weeks, then increases to 5mg weekly as the initial maintenance dose 6. However, for a patient resuming after a gap who previously tolerated 5mg, the 5mg dose is appropriate 1, 6.
Monitoring After Resumption
Week 1-4 post-resumption: Assess for gastrointestinal tolerance (nausea, vomiting, diarrhea) at week 4 before considering any dose escalation 1, 3. Expected incidence rates are nausea 17-22%, diarrhea 13-16%, vomiting 6-10% 7, 5.
Hypoglycemia surveillance: If the patient is on insulin or sulfonylureas, monitor blood glucose frequently during the first 4 weeks 1, 6. Tirzepatide alone carries minimal intrinsic hypoglycemia risk (0.2-1.7% in clinical trials), but risk increases when combined with insulin secretagogues 7, 5.
Blood pressure monitoring: Check blood pressure every 4 weeks during the initial period, as weight loss may necessitate antihypertensive medication adjustment 3.
Efficacy evaluation at 12-16 weeks: Re-assess HbA1c, weight, and treatment goals 1, 3. If weight loss is <5% after 3 months at therapeutic dose, consider discontinuation or alternative approaches 1, 3.
Common Pitfalls to Avoid
Do not restart at 2.5mg in a patient who previously tolerated 5mg; this unnecessarily delays therapeutic benefit 3.
Do not assume the patient can immediately escalate to 10mg after resuming at 5mg; maintain the 5mg dose for at least 4 weeks before considering escalation 6, 5.
Do not overlook concomitant medication adjustments: Failure to reduce insulin or sulfonylureas when restarting tirzepatide significantly increases hypoglycemia risk 1, 6.
Do not prescribe if new contraindications have emerged: Screen for medullary thyroid carcinoma, MEN 2, or new gallbladder disease 1, 3, 4, 5.
Expected Outcomes
The patient should experience similar efficacy to their prior treatment course. In clinical trials, tirzepatide 5mg produced HbA1c reductions of approximately 1.9-2.1% and weight loss of about 5.5 kg 7, 8, 5. Gastrointestinal side effects are typically mild-to-moderate and transient, decreasing over time with continued exposure 7, 5.
The key determinant is prior tolerance: If the patient tolerated 5mg well before the 5-week gap without significant nausea, vomiting, or other adverse effects, resuming at this dose is both safe and appropriate 1.